MicroRNA-99b acts as a tumor suppressor in non-small cell lung cancer by directly targeting fibroblast growth factor receptor 3

Experimental and Therapeutic Medicine

Volumn 3, Issue 1, 2012, Pages 149-153

  Kang, Jaeku ^a   Lee, Soo Young ^b   Lee, Sun Young ^c   Kim, Young Jin ^c   Park, Jae Yong ^d   Kwon, Sun Jung ^c   Na, Moon Jun ^c   Lee, Eun Jin ^e   Jeon, Hyo Sung ^e   Son, Ji Woong ^b,c  

^a Department of Biochemistry and Molecular Biology   (South Korea)

^b Konyang University   (South Korea)

^c Konyang University College of Medicine   (South Korea)

^d Kyungpook National University Hospital   (South Korea)

^e Kyungpook National University School of Medicine   (South Korea)

Author keywords

Fibroblast growth factor receptor 3; Lung cancer; microRNA; Tumor suppressor

Indexed keywords

FIBROBLAST GROWTH FACTOR RECEPTOR 3; MICRORNA; MICRORNA 99B; UNCLASSIFIED DRUG;

3' UNTRANSLATED REGION; ARTICLE; CANCER CELL; CANCER GROWTH; CANCER INHIBITION; CELL PROLIFERATION; CLINICAL ARTICLE; COLONY FORMATION; CONTROLLED STUDY; DOWN REGULATION; HUMAN; HUMAN CELL; HUMAN TISSUE; LUNG NON SMALL CELL CANCER; PRECANCER; PROTEIN EXPRESSION; PROTEIN RNA BINDING; PROTEIN SYNTHESIS INHIBITION; PROTEIN TARGETING; RECEPTOR UPREGULATION; RNA ANALYSIS; RNA SYNTHESIS;

EID: 84855382989     PISSN: 17920981     EISSN: 17921015     Source Type: Journal    
DOI: 10.3892/etm.2011.366     Document Type: Article

References (32)

1. Ambros V: The functions of animal microRNAs. Nature 431: 350-355, 2004.
2. Kim VN and Nam J-W: Genomics of microRNA. Trends Genet 22: 165-173, 2006.
3. Schetter AJ, Heegaard NHH and Harris CC: Inflammation and cancer: interweaving microRNA, free radical, cytokine and p53 pathways. Carcinogenesis 31: 37-49, 2010.
4. Kwak PB, Iwasaki S and Tomari Y: The microRNA pathway and cancer. Cancer Sci 101: 2309-2315, 2010.
5. Volinia S, Calin GA, Liu C-G, et al: A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci USA 103: 2257-2261, 2006.
6. Yanaihara N, Caplen N, Bowman E, et al: Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. Cancer Cell 9: 189-198, 2006.
7. Son J-W, Kim Y-J, Cho H-M, et al: MicroRNA expression profiles in Korean non-small cell lung. Tuberc Respir Dis 67: 413-421, 2009.
8. Cheng AM, Byrom MW, Shelton J and Ford LP: Antisense inhibition of human miRNAs and indications for an involvement of miRNA in cell growth and apoptosis. Nucleic Acids Res 33: 1290-1297, 2005.
9. Chen C-Z, Li L, Lodish HF and Bartel DP: MicroRNAs modulate hematopoietic lineage differentiation. Science 303: 83-86, 2004.
10. Esquela-Kerscher A, Trang P, Wiggins JF, et al: The let-7 microRNA reduces tumor growth in mouse models of lung cancer. Cell Cycle 7: 759-764, 2008.
11. Ma L, Young J, Prabhala H, et al: miR-9, a MYC/MYCN-activated microRNA, regulates E-cadherin and cancer metastasis. Nat Cell Biol 12: 247-256, 2010.
12. Lewis BP, Burge CB and Bartel DP: Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell 120: 15-20, 2005.
13. Lamont FR, Tomlinson DC, Cooper PA, Shnyder SD, Chester JD and Knowles MA: Small molecule FGF receptor inhibitors block FGFR-dependent urothelial carcinoma growth in vitro and in vivo. Br J Cancer 104: 75-82, 2011.
14. Ornitz DM, Xu J, Colvin JS, et al: Receptor specificity of the fibroblast growth factor family. J Biol Chem 271: 15292-15297, 1996.
15. Haugsten EM, Wiedlocha A, Olsnes S and Wesche J: Roles of fibroblast growth factor receptors in carcinogenesis. Mol Cancer Res 8: 1439-1452, 2010.
16. Hanahan D and Weinberg RA: The hallmarks of cancer. Cell 100: 57-70, 2000.
17. Webster RJ, Giles KM, Price KJ, Zhang PM, Mattick JS and Leedman PJ: Regulation of epidermal growth factor receptor signaling in human cancer cells by microRNA-7. J Biol Chem 284: 5731-5741, 2009.
18. Cho WC, Chow AS and Au JS: MiR-145 inhibits cell proliferation of human lung adenocarcinoma by targeting EGFR and NUDT1. RNA Biol 8: 125-131, 2011.
19. Garofalo M, Di Leva G, Romano G, et al: miR-221&222 regulate TRAIL resistance and enhance tumorigenicity through PTEN and TIMP3 downregulation. Cancer Cell 16: 498-509, 2009.s
20. Nasser MW, Datta J, Nuovo G, et al: Down-regulation of micro-RNA-1 (miR-1) in lung cancer. J Biol Chem 283: 33394-33405, 2008.
21. Billerey C, Chopin D, Aubriot-Lorton M-H, et al: Frequent FGFR3 mutations in papillary non-invasive bladder (pTa) tumors. Am J Pathol 158: 1955-1959, 2001.
22. Cappellen D, De Oliveira C, Ricol D, et al: Frequent activating mutations of FGFR3 in human bladder and cervix carcinomas. Nat Genet 23: 18-20, 1999.
23. Kang S, Dong S, Gu T-L, et al: FGFR3 activates RSK2 to mediate hematopoietic transformation through tyrosine phosphorylation of RSK2 and activation of the MEK/ERK pathway. Cancer Cell 12: 201-214, 2007.
24. Cheng L, Zhang S, Davidson DD, et al: Molecular determinants of tumor recurrence in the urinary bladder. Future Oncol 5: 843-857, 2009.
25. Chesi M, Nardini E, Brents LA, et al: Frequent translocation t(4;14)(p16.3;q32.3) in multiple myeloma is associated with increased expression and activating mutations of fibroblast growth factor receptor 3. Nat Genet 16: 260-264, 1997.
26. Tomlinson DC, Baldo O, Harnden P and Knowles MA: FGFR3 protein expression and its relationship to mutation status and prognostic variables in bladder cancer. J Pathol 213: 91-98, 2007.
27. Karoui M, Hofmann-Radvanyi H, Zimmermann U, et al: No evidence of somatic FGFR3 mutation in various types of carcinoma. Oncogene 20: 5059-5061, 2001.
28. Woenckhaus M, Merk J, Stoehr R, et al: Prognostic value of FHIT, CTNNB1, and MUC1 expression in non-small cell lung cancer. Hum Pathol 39: 126-136, 2008.
29. Thomson S, Petti F, Sujka-Kwok I, Epstein D and Haley J: Kinase switching in mesenchymal-like non-small cell lung cancer lines contributes to EGFR inhibitor resistance through pathway redundancy. Clin Exp Metastasis 25: 843-854, 2008.
30. Marek L, Ware KE, Fritzsche A, et al: Fibroblast growth factor (FGF) and FGF receptor-mediated autocrine signaling in non-small-cell lung cancer cells. Mol Pharmacol 75: 196-207, 2009.
31. Kono SA, Marshall ME, Ware KE and Heasley LE: The fibroblast growth factor receptor signaling pathway as a mediator of intrinsic resistance to EGFR-specific tyrosine kinase inhibitors in non-small cell lung cancer. Drug Resist Updat 12: 95-102, 2009.
32. Iwatsuki M, Mimori K, Yokobori T, et al: Epithelial-mesenchymal transition in cancer development and its clinical significance. Cancer Sci 101: 293-299, 2010.